| abstract |
The present invention relates to a pharmaceutical aerosol formulation for administration using a pressurized metered dose inhaler containing an active ingredient selected from formoterol or its stereoisomer, a physiologically acceptable salt and solvate, in a solution of liquefied HFA (hydrofluoroalkane) propellant and a co-solvent, characterized in that the amount of residual water is less than 1500 ppm of the total weight of the drug, and to the metered dose inhaler under pressure for the administration of the specified drug for the treatment of respiratory x diseases such as asthma and chronic obstructive pulmonary disease (COPD). |